Lysteda

Lysteda is a brand name of tranexamic acid, approved by the FDA in the following formulation(s):

LYSTEDA (tranexamic acid - tablet; oral)

• 
  Manufacturer: FERRING PHARMS AS
  
  Approval date: November 13, 2009
  
  Strength(s): 650MG ^[RLD]

Has a generic version of Lysteda been approved?

No. There is currently no therapeutically equivalent version of Lysteda available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lysteda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tranexamic acid formulations
  Patent 7,947,739
  Issued: May 24, 2011
  Inventor(s): Moore; Keith A. & Heasley; Ralph A. & Greiwe; Jeffrey S. & Facemire; John W. & Modest; Jason D.
  Assignee(s): Ferring B.V.
  Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
  
  Patent expiration dates:
  
  
  • March 4, 2025
    
    ✓ 
    Drug product
  
  



• 
  Tranexamic acid formulations
  Patent 8,022,106
  Issued: September 20, 2011
  Inventor(s): Moore; Keith A. & Heasley; Ralph A. & Greiwe; Jeffrey S. & Facemire; John W. & Modest; Jason D.
  Assignee(s): Ferring B.V.
  Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
  
  Patent expiration dates:
  
  
  • March 4, 2025
    
    ✓ 
    Patent use: TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 13, 2012 - NEW DOSAGE FORM
  
  

See also...

• Lysteda Consumer Information (Drugs.com)
• Lysteda Consumer Information (Wolters Kluwer)
• Lysteda Consumer Information (Cerner Multum)
• Lysteda Advanced Consumer Information (Micromedex)
• Tranexamic Acid Consumer Information (Wolters Kluwer)
• Tranexamic Acid Tablet Consumer Information (Wolters Kluwer)
• Tranexamic acid Consumer Information (Cerner Multum)
• Tranexamic acid Advanced Consumer Information (Micromedex)
• Tranexamic acid Intravenous Advanced Consumer Information (Micromedex)